Literature DB >> 7032269

Clonidine, a centrally acting sympathetic inhibitor, as monotherapy for mild to moderate hypertension.

C Thananopavarn, M S Golub, P Eggena, J D Barrett, M P Sambhi.   

Abstract

Sixteen patients with uncomplicated essential hypertension were treated with 0.2 mg of clonidine three times daily as the sole antihypertensive drug. Blood pressure decreased from 167 +/- 4/105 +/- 2 to 139 +/- 3/89 +/- 2 mm Hg (mean +/- standard error of the mean) after 1 week (p less than 0.001) and remained at 140 +/- 3/90 +/- 2 mm Hg after 3 months of therapy. There were no significant changes in cardiac output, blood volume, renal blood flow or glomerular filtration rate during clonidine therapy. Clonidine significantly decreased plasma catecholamines and there was a linear correlation between the change in blood pressure and decreases in plasma catecholamine concentration (r = 0.61, p less than 0.001). There was also a significant correlation between the decreases in heart rate and blood pressure (r = 0.78, p less than 0.001). It is concluded that clonidine can be used effectively and safely as the sole agent in the treatment of mild to moderate hypertension.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7032269     DOI: 10.1016/0002-9149(82)90289-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  Clonidine in spinal cord injury.

Authors:  P W Nance; A H Shears; D M Nance
Journal:  Can Med Assoc J       Date:  1985-07-01       Impact factor: 8.262

2.  Translating safety, efficacy and compliance into economic value for controlled release dosage forms.

Authors:  M P Cramer; S R Saks
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

Review 3.  Pharmacokinetic considerations in the use of newer transdermal formulations.

Authors:  G Ridout; G C Santus; R H Guy
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

Review 4.  Renal effects of antihypertensive drugs.

Authors:  W A Schlueter; D C Batlle
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

5.  Natriuretic and water diuretic effects of guanabenz, a central alpha-2 agonist.

Authors:  M Goldberg; M Gehr; E P MacCarthy
Journal:  Trans Am Clin Climatol Assoc       Date:  1984

Review 6.  Clinical pharmacokinetics of clonidine.

Authors:  D T Lowenthal; K M Matzek; T R MacGregor
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

7.  Crossover comparison of moxonidine and clonidine in mild to moderate hypertension.

Authors:  V Plänitz
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 8.  How Do Antihypertensive Drugs Work? Insights from Studies of the Renal Regulation of Arterial Blood Pressure.

Authors:  Holly Digne-Malcolm; Matthew C Frise; Keith L Dorrington
Journal:  Front Physiol       Date:  2016-07-29       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.